Perlegen Sciences has inked a collaboration deal with the cancer drug pioneer Genentech to study the genetics of cancer. Their work is aimed at developing new therapies and diagnostic tools for cancer. Perlegen's high throughput oligonucleotide array approach utilizes Affymetrix GeneChip technology. Growing knowledge about genetics is expected to play a major role in developing a new generation of cancer drugs. Terms of the deal were not disclosed. This is the second big pact for Perlegen in 10 days, following an announced tie-up with Pfizer.
- read this release for more